EPIX RECEIVES APPROVABLE LETTER FOR BLOOD POOL CONTRAST AGENT

Epix Pharmaceuticals has received an approvable letter from the FDA for MS-325, a blood pool management agent for magnetic resonance angiography (MRA).

The FDA requested additional information from Epix to support the application for MS-325 (gadofosveset trisodium) in enhanced MRA. Epix is developing the agent in conjunction with Schering AG.